Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?
You may also be interested in...
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.